Active Ingredient: Evolocumab
Homozygous familial hypercholesterolemia:
Adjunct to diet and other LDL-lowering therapies (eg, statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C
Hyperlipidemia, primary (including heterozygous familial hyperlipidemia):
Adjunct to diet, alone or in combination with other lipid-lowering therapies (eg, maximum tolerated dose of statins), for the treatment of adults with primary hyperlipidemia, including heterozygous familial hyperlipidemia (HeFH), to reduce LDL-C.
Prevention of cardiovascular events in patients with established cardiovascular disease:
To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease (CVD).